Abstract
PI3K is a large duel lipid and protein kinase that catalyzes phosphorylation of the 3-hydroxyl position of phosphatidylinositides (PIs) and plays a crucial role in the cellular signaling network. Inhibition of the phosphatidylinositol 3- kinase (PI3K) signaling pathway is a newly identified strategy for the discovery and development of certain therapeutic agents. Among the various subtypes of PI3K, class IA PI3Kα has gained increasing attention as a promising drug target for the treatment of cancer due to its frequent mutations and amplifications in various human cancers. Here, we discuss the insights gained so far relevant to the development of PI3K inhibitors for the treatment of human cancers. Emphasis is on the structure-activity relationship of PI3K inhibitors which bear the most significant PI3Kα inhibitory activities. We also highlight PI3K inhibitors that are currently under clinical trials for cancers.
Keywords: PI3K inhibitor, PI3Kα, anticancer, structure-activity relationship (SAR), clinical trial
Current Medicinal Chemistry
Title: PI3K Inhibitors for Cancer Therapy: What has been Achieved So Far?
Volume: 16 Issue: 8
Author(s): Peng Wu, Tao Liu and Yongzhou Hu
Affiliation:
Keywords: PI3K inhibitor, PI3Kα, anticancer, structure-activity relationship (SAR), clinical trial
Abstract: PI3K is a large duel lipid and protein kinase that catalyzes phosphorylation of the 3-hydroxyl position of phosphatidylinositides (PIs) and plays a crucial role in the cellular signaling network. Inhibition of the phosphatidylinositol 3- kinase (PI3K) signaling pathway is a newly identified strategy for the discovery and development of certain therapeutic agents. Among the various subtypes of PI3K, class IA PI3Kα has gained increasing attention as a promising drug target for the treatment of cancer due to its frequent mutations and amplifications in various human cancers. Here, we discuss the insights gained so far relevant to the development of PI3K inhibitors for the treatment of human cancers. Emphasis is on the structure-activity relationship of PI3K inhibitors which bear the most significant PI3Kα inhibitory activities. We also highlight PI3K inhibitors that are currently under clinical trials for cancers.
Export Options
About this article
Cite this article as:
Wu Peng, Liu Tao and Hu Yongzhou, PI3K Inhibitors for Cancer Therapy: What has been Achieved So Far?, Current Medicinal Chemistry 2009; 16 (8) . https://dx.doi.org/10.2174/092986709787581905
DOI https://dx.doi.org/10.2174/092986709787581905 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
AAVs Anatomy: Roadmap for Optimizing Vectors for Translational Success
Current Gene Therapy Design of New Improved Curcumin Derivatives to Multi-targets of Cancer and Inflammation
Current Drug Targets Emerging Electrical Biosensors for Detecting Pathogens and Antimicrobial Susceptibility Tests
Current Organic Chemistry Heparanase as a Target in Cancer Therapy
Current Cancer Drug Targets The p53-Estrogen Receptor Loop in Cancer
Current Molecular Medicine Targeting Hypoxia for Sensitization of Tumors to Radio- and Chemotherapy
Current Cancer Drug Targets Anticarcinogenic Actions of Tributyrin, A Butyric Acid Prodrug
Current Drug Targets Discovery of Hedgehog Antagonists for Cancer Therapy
Current Medicinal Chemistry Surgical Staging for Cervical Cancer
Current Women`s Health Reviews The Immunoregulatory Protein Human B7H3 is a Tumor-Associated Antigen that Regulates Tumor Cell Migration and Invasion
Current Cancer Drug Targets Jaridonin, a Novel Ent-Kaurene Diterpenoid from Isodon rubescens, Inducing Apoptosis via Production of Reactive Oxygen Species in Esophageal Cancer Cells
Current Cancer Drug Targets Immunotherapeutic Options for Pediatric Malignancies
Current Immunology Reviews (Discontinued) Development of a Registry for Down Syndrome in the Gulf Area of the Middle East
Applied Clinical Research, Clinical Trials and Regulatory Affairs The CCL2/CCR2 Axis in the Pathogenesis of HIV-1 Infection: A New Cellular Target for Therapy?
Current Drug Targets Association Between Chlamydia pneumoniae Antibodies and Lung Cancer: A Meta-Analysis
Current Respiratory Medicine Reviews Progress in the Discovery of Polo-like Kinase Inhibitors
Current Topics in Medicinal Chemistry Engineered Peptides for Applications in Cancer-Targeted Drug Delivery and Tumor Detection
Mini-Reviews in Medicinal Chemistry Two Diseases with One Hit: Inhibiting a Potential Diabetes Target to Reduce Cancer Risk and to Improve Anti-Cancer Therapy
Current Cancer Therapy Reviews Radiolabeled Oligonucleotides for Antisense Imaging
Current Organic Synthesis Use of Liposomal Drugs in the Treatment of Rheumatoid Arthritis
Current Rheumatology Reviews